ADA 2024
June 21–24, 2022 | Orlando, FL
June 2024
Carelon Research is presenting our latest research at the world’s largest meeting on diabetes: American Diabetes Association’s hybrid 84th Scientific Sessions: ADA 2024.
Carelon Research presentations
Carelon Research authors are indicated in bold
*Associate at time of study.
|
Presentation |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Poster Saturday, June 22, 2024 |
Session: Late breaking poster session |
[1864-LB] Comparative safety and effectiveness of GLP-1 RA and SGLT2i use in adults with type 2 diabetes in US clinical practice |
Hoffman S[1], Lanes, S[1], Quimbo T[1], Papazian A[1], White J[2], Fisher V[2], Cziraky MJ[1], Crowley MJ[3], Willey VJ[1] |
[1]Carelon Research, Wilmington, DE, [2]Carelon Rx, Costa Mesa, CA, [3]Durham VA Medical Center, Durham, NC |
|
Poster Saturday, June 22, 2024 |
Session: Late breaking poster session (23-B Obesity – human) |
[2084-LB] Real-world effectiveness of tirzepatide among people with obesity or overweight without type 2 diabetes (T2D) |
Hankosky E[1], Desai K[2], Chinthammit C[1], Grabner M[2], Stockbower G[2], He X[1], Mojdami D[1], Wenziger C[2], Gibble T[1] |
[1]Eli Lilly and Company, Indianapolis, IN [2]Carelon Research, Wilmington, DE |
|
Oral Saturday, June 22, 2024 |
Session: Oral presentations – leveling up incretin-based therapy in type 2 diabetes |
[230-OR] Comparative effectiveness of semaglutide in type 2 diabetes — year 2 results of a randomized pragmatic clinical trial |
Buse JB[1], Soule BP[2], Harty BJ[3], Christensen HN [1], Cziraky MJ[3], Willey VJ[3], Skibsted S[2] |
[1 ] University of North Carolina School of Medicine, Chapel Hill, NC, USA; [2]Novo Nordisk A/S, Søborg, Denmark; [3] Carelon Research, Wilmington, DE, USA |
|
ePoster Theater Sunday, June 23, 2024 |
Session: Improving efficacy and safety of incretin-based therapies |
[738-P] Real-world effectiveness among patients with type 2 diabetes (T2D) initiating tirzepatide (TZP) |
Mody R[1], Desai K[2], Teng CC[2], Reznor G[1], Stockbower G[2], Grabner, M[2], Benneyworth BD[1] |
[1]Eli Lilly and Company, Indianapolis, IN [2]Carelon Research, Wilmington, DE |
|
Poster Sunday, June 23, 2024 |
Session: 12-B clinical therapeutics – incretin-based therapies |
[738-P] Real-world effectiveness among patients with type 2 diabetes (T2D) initiating tirzepatide (TZP) |
Mody R[1], Desai K[2], Teng CC[2], Reznor G[1], Stockbower G[2], Grabner, M[2], Benneyworth BD[1] |
[1]Eli Lilly and Company, Indianapolis, IN [2]Carelon Research, Wilmington, DE |
|
Poster Sunday, June 23, 2024 |
Session: 12-B clinical therapeutics – incretin-based therapies |
[744-P] Dosing patterns of tirzepatide (TZP) in patients with type 2 diabetes (T2D) from a commercially insured US population |
Mody R[1], Desai K[2], Teng CC[2], Reznor G[1], Stockbower G[2], Grabner, M[2], Benneyworth BD[1] |
[1]Eli Lilly and Company, Indianapolis, IN [2]Carelon Research, Wilmington, DE |
|
Poster Sunday, June 23, 2024 |
Session: Sunday general poster session |
[1079-P] Assessing clinical inertia on implementing guideline recommendations in patients with type 2 diabetes: The ACTION study |
Stephenson JJ[1], Witkowski N2, Smith J[1]*, Wong AC[2], Bengtson LGS[2], Willey VJ[1] |
[1]Carelon Research, Wilmington, DE [2]Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT |
